An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Axonics, a medical technology company specializing in bladder and bowel dysfunction treatments, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, at 4:30 p.m. PT on January 11. In advance, Axonics will release preliminary unaudited 2022 financial results and initial 2023 guidance before the market opens on the same day. The company ranks first on the Financial Times' 2022 fastest-growing companies in the Americas and fourth on Deloitte's Technology Fast 500.
Positive
None.
Negative
None.
IRVINE, Calif.--(BUSINESS WIRE)--
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Axonics is scheduled to present at 4:30 p.m. Pacific Time on Wednesday, January 11. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website.
In advance of the presentation and scheduled investor meetings, Axonics will issue a press release before the market opens on January 11 that provides preliminary unaudited 2022 financial results and initial 2023 financial guidance.
About Axonics®
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500™ following its No. 1 ranking in 2021.
Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.
When will Axonics present at the J.P. Morgan Healthcare Conference?
Axonics will present at the J.P. Morgan Healthcare Conference on January 11 at 4:30 p.m. PT.
What financial information will Axonics release on January 11?
Axonics will release its preliminary unaudited 2022 financial results and initial 2023 financial guidance on January 11 before the market opens.
Where can I access Axonics' presentation from the J.P. Morgan Healthcare Conference?
The presentation can be accessed via a live webcast and archived replay on the Axonics investor relations website.
What is Axonics' ranking in the Financial Times 2022 report?
Axonics was ranked No. 1 in the Financial Times' 2022 ranking of the 500 fastest-growing companies in the Americas.
What are the focuses of Axonics' medical products?
Axonics develops products for treating bladder and bowel dysfunction, including sacral neuromodulation systems and hydrogel for stress urinary incontinence.
